Holguin's Work in Clinical Trials Highlighted
- Written by Lourdes Pichs Rodríguez
- Published in Health
- Hits: 2316
The role of the province of Holguin in the inclusion of patients in clinical trials was highlighted during the Clinical Trials Management Workshop of the Molecular Immunology Center (CIM), held in the eastern territory.
Specialists agreed to value as positive the discipline demonstrated by specialists and institutions of primary and secondary health care in the development of these researches, through which it is possible to evaluate the efficacy and safety of medicines, mostly against diseases that today are among the leading causes of death in Cuba, such as oncological diseases.
Of the three clinical trials (EC) started in 1996, Holguin currently adds 93 and this year will develop 24 in the three provincial hospitals and primary health care, as explained by Dr. Zaimar Rodriguez, head of the EC network in the territory.
Among the open clinical trials in the province are the CIMAher® (Nimotuzumab) in the treatment of locally advanced or metastatic pancreatic tumors and the vaccine preparation NGcGM3 / VSSP in patients with metastatic breast cancer with positive hormone receptors and HER2 negative.
Several of the specialists who head the different researches with Cuban products revealed results of some studies developed in the province, such as the use of the drug neuro EPO, a variant of erythropoietin with low sialic acid content, in patients with dominant hereditary ataxias.
After one year under study, "stability of the disease was observed in the treated cases and not in the placebo", according to the report presented.
The CIM has 12 products for clinical research in 2019, including the Nimotuzumab MAb for prostate cancer, pancreas, esophagus; the CIMAvax EGF vaccine (lung, prostate and bladder); the T1h Itolizumab MAb (psoriasis, multiple sclerosis) and the NGGM3 vaccine (breast, melanoma, SCLC).
